Suppression of lung cancer in murine model: treated by combination of recombinant human endostsatin adenovirus with low-dose cisplatin
Open Access
- 5 March 2009
- journal article
- research article
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 28 (1) , 31
Abstract
Background: The sustained growth of tumors necessitates neovascularization. As one of the potent endogenous vascular inhibitors, endostatin has been widely used in antiangiogenesis therapy for tumor. Cisplatin is normally administered in chemotherapy for lung cancer but accompanied with serious side effects. In the current study, we investigated a novel chemo-antiangiogenesis therapeutic strategy to both improve toxic effects on lung cancer cells and reduce damages to normal cells in the anti-tumor therapy. Methods: In vitro, we transduced LLC cells with Ad-hEndo and collected supernatants. Western blotting analysis of the supernatants revealed expression of endostatin. In vivo, to fully investigate the suppression effect on murine lung cancer of the combination therapy, we injected recombinant human endostatin adenovirus intratumorally plus a low dose of cisplatin intraperitoneally routinely. The tumor volume and survival time were observed. Angiogenesis was apparently inhibited within the tumor tissues and on the alginate beads. Assessment of apoptotic cells by the TUNEL assay was conducted in the tumor tissues. Results: The combination treatment significantly suppressed the tumor growth and prolonged survival time of the murine LLC tumor model. This anti-tumor activity was associated with decreased microvessel density and increased apoptotic index of tumor cells. Conclusion: According to the results in this study, recombinant human endostatin adenovirus in combination with a low dose of cisplatin demonstrated apparent synergistic anti-tumor activity without marked toxicity. Thus, these observations may provide a rational alternative for lung cancer treatment.Keywords
This publication has 22 references indexed in Scilit:
- Antiangiogenesis in haematological malignanciesBritish Journal of Haematology, 2008
- Bevacizumab in the treatment of breast cancerExpert Review of Anticancer Therapy, 2008
- Targeting Angiogenesis in the Treatment of Lung CancerJournal of Thoracic Oncology, 2008
- Endostatin, an antiangiogenic protein, is expressed in the unilateral ureteral obstruction mice modelJournal Of Nephrology, 2008
- Anti-Angiogenic Gene Therapy for Metastatic Renal Cell Carcinoma Produces Tumor Growth Suppression in an Athymic Nude Mouse ModelJournal of Urology, 2008
- Antiangiogenesis in cancer therapy—endostatin and its mechanisms of actionExperimental Cell Research, 2006
- Synergistic anti-tumor effect of recombinant human endostatin adenovirus combined with gemcitabineAnti-Cancer Drugs, 2005
- Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastasesProceedings of the National Academy of Sciences, 2000
- Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor GrowthCell, 1997
- Tumor Angiogenesis and Metastasis — Correlation in Invasive Breast CarcinomaNew England Journal of Medicine, 1991